Patents by Inventor Julie A. McEarchern

Julie A. McEarchern has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SYNERGISTIC EFFECTS BETWEEN AURISTATIN-BASED ANTIBODY DRUG CONJUGATES AND INHIBITORS OF THE PI3K-AKT MTOR PATHWAY
    Publication number: 20240131176
    Abstract: The present invention is directed to methods for treating cancer comprising administering to a subject in need thereof an auristatin-based antibody drug conjugate and an inhibitor of the PI3K-AKT-mTOR pathway.
    Type: Application
    Filed: February 9, 2023
    Publication date: April 25, 2024
    Inventors: Timothy S. Lewis, Che-Leung Law, Julie A. McEarchern
  • Synergistic effects between auristatin-based antibody drug conjugates and inhibitors of the PI3K-AKT mTOR pathway
    Patent number: 11607460
    Abstract: The present invention is directed to methods for treating cancer comprising administering to a subject in need thereof an auristatin-based antibody drug conjugate and an inhibitor of the PI3K-AKT-mTOR pathway.
    Type: Grant
    Filed: December 19, 2018
    Date of Patent: March 21, 2023
    Assignee: SEAGEN INC.
    Inventors: Timothy S. Lewis, Che-Leung Law, Julie A. McEarchern
  • SYNERGISTIC EFFECTS BETWEEN AURISTATIN-BASED ANTIBODY DRUG CONJUGATES AND INHIBITORS OF THE PI3K-AKT MTOR PATHWAY
    Publication number: 20190184029
    Abstract: The present invention is directed to methods for treating cancer comprising administering to a subject in need thereof an auristatin-based antibody drug conjugate and an inhibitor of the PI3K-AKT-mTOR pathway.
    Type: Application
    Filed: December 19, 2018
    Publication date: June 20, 2019
    Inventors: Timothy S. Lewis, Che-Leung Law, Julie A. McEarchern
  • Synergistic effects between auristatin-based antibody drug conjugates and inhibitors of the PI3K-AKT mTOR pathway
    Patent number: 10201615
    Abstract: The present invention is directed to methods for treating cancer comprising administering to a subject in need thereof an auristatin-based antibody drug conjugate and an inhibitor of the PI3K-AKT-mTOR pathway.
    Type: Grant
    Filed: January 27, 2016
    Date of Patent: February 12, 2019
    Assignee: SEATTLE GENETICS, INC.
    Inventors: Timothy S. Lewis, Che-Leung Law, Julie A. McEarchern
  • SYNERGISTIC EFFECTS BETWEEN AURISTATIN-BASED ANTIBODY DRUG CONJUGATES AND INHIBITORS OF THE PI3K-AKT MTOR PATHWAY
    Publication number: 20160220693
    Abstract: The present invention is directed to methods for treating cancer comprising administering to a subject in need thereof an auristatin-based antibody drug conjugate and an inhibitor of the PI3K-AKT-mTOR pathway.
    Type: Application
    Filed: January 27, 2016
    Publication date: August 4, 2016
    Inventors: Timothy S. Lewis, Che-Leung Law, Julie A. McEarchern
  • Synergistic effects between auristatin-based antibody drug conjugates and inhibitors of the PI3K-AKT mTOR pathway
    Patent number: 9272052
    Abstract: The present invention is directed to methods for treating cancer comprising administering to a subject in need thereof an auristatin-based antibody drug conjugate and an inhibitor of the PI3K-AKT-mTOR pathway.
    Type: Grant
    Filed: October 20, 2011
    Date of Patent: March 1, 2016
    Assignee: SEATTLE GENETICS, INC.
    Inventors: Timothy S. Lewis, Che-Leung Law, Julie A. McEarchern
  • Anti-CD70 antibody and its use for the treatment of cancer and immune disorders
    Patent number: 9051372
    Abstract: Disclosed are CD70 binding agents, such as anti-CD70 antibodies and derivatives, that induce a cytotoxic, cytostatic or immunosuppressive without conjugation to a therapeutic agents, as well as pharmaceutical compositions and kits comprising the antibody or derivative. Also disclosed are methods for the treatment and prevention of CD70-expressing cancers and immunological disorders comprising administering to a subject the CD70-binding agent.
    Type: Grant
    Filed: November 5, 2008
    Date of Patent: June 9, 2015
    Assignee: Seattle Genetics, Inc.
    Inventors: Che-Leung Law, Julie McEarchern, Alan F. Wahl
  • Anti-CD70 antibody-drug conjugates and their use for the treatment and prevention of cancer and immune disorders
    Patent number: 8663642
    Abstract: Disclosed are anti-CD70 antibodies and derivatives thereof conjugated to cytotoxic, immunosuppressive, or other therapeutic agents, as well as pharmaceutical compositions and kits comprising the antibody- and antibody derivative-drug conjugates. Also disclosed are methods, for the treatment of CD70-expressing cancers and immunological disorders, comprising administering to a subject the disclosed pharmaceutical compositions.
    Type: Grant
    Filed: September 27, 2010
    Date of Patent: March 4, 2014
    Assignee: Seattle Genetics, Inc.
    Inventors: Che-Leung Law, Julie McEarchern, Jonathan G. Drachman
  • Treatment of immune disorders with anti-CD70 antibody
    Patent number: 8647624
    Abstract: Disclosed are CD70 binding agents, such as anti-CD70 antibodies and derivatives, that induce a cytotoxic, cytostatic or immunosuppressive without conjugation to a therapeutic agents, as well as pharmaceutical compositions and kits comprising the antibody or derivative. Also disclosed are methods for the treatment and prevention of CD70-expressing cancers and immunological disorders comprising administering to a subject the CD70-binding agent.
    Type: Grant
    Filed: January 18, 2008
    Date of Patent: February 11, 2014
    Assignee: Seattle Genetics, Inc.
    Inventors: Che-Leung Law, Julie McEarchern, Alan F. Wahl
  • Humanized anti-CD70 binding agents and uses thereof
    Patent number: 8562987
    Abstract: Disclosed are CD70 binding agents, such as humanized anti-CD70 antibodies and fragments and derivatives, that exert a cytotoxic, cytostatic or immunomodulatory on CD70 expressing cells, as well as pharmaceutical compositions and kits comprising the antibody, fragment or derivative. Also disclosed are methods for the treatment of CD70-expressing cancers and immunological disorders, comprising administering to a subject the CD70 binding agents or pharmaceutical compositions.
    Type: Grant
    Filed: October 11, 2011
    Date of Patent: October 22, 2013
    Assignee: Seattle Genetics, Inc.
    Inventors: Charlotte McDonagh, Paul Carter, Julie McEarchern, Che-Leung Law
  • Synergistic Effects Between Auristatin-Based Antibody Drug Conjugates And Inhibitors Of The PI3K-AKT mTOR Pathway
    Publication number: 20130209496
    Abstract: The present invention is directed to methods for treating cancer comprising administering to a subject in need thereof an auristatin-based antibody drug conjugate and an inhibitor of the PI3K-AKT-mTOR pathway.
    Type: Application
    Filed: October 20, 2011
    Publication date: August 15, 2013
    Applicant: Seatle Genetics, Inc.
    Inventors: Timothy S. Lewis, Che-Leung Law, Julie A. McEarchern
  • Anti-CD70 antibody and its use for the treatment and prevention of cancer and immune disorders
    Patent number: 8337838
    Abstract: Disclosed are CD70 binding agents, such as anti-CD70 antibodies and derivatives, that induce a cytotoxic, cytostatic or immunomodulatory without conjugation to a therapeutic agents as well as pharmaceutical compositions and kits comprising the antibody or derivative. Also disclosed are methods for the treatment and prevention of CD70-expressing cancers and immunological disorders comprising administering the CD70 binding agents to a subject.
    Type: Grant
    Filed: February 12, 2009
    Date of Patent: December 25, 2012
    Assignee: Seattle Genetics, Inc.
    Inventors: Che-Leung Law, Julie McEarchern, Alan F. Wahl
  • Anti-CD70 Antibody and Its Use for the Treatment and Prevention of Cancer and Immune Disorders
    Publication number: 20120294863
    Abstract: Disclosed are CD70 binding agents, such as anti-CD70 antibodies and derivatives, that induce a cytotoxic, cytostatic or immunomodulatory without conjugation to a therapeutic agents as well as pharmaceutical compositions and kits comprising the antibody or derivative. Also disclosed are methods for the treatment and prevention of CD70-expressing cancers and immunological disorders comprising administering the CD70 binding agents to a subject.
    Type: Application
    Filed: August 3, 2012
    Publication date: November 22, 2012
    Applicant: Seattle Genetics, Inc.
    Inventors: Che-Leung Law, Julie McEarchern, Alan F. Wahl
  • Humanized Anti-CD70 Binding Agents and Uses Thereof
    Publication number: 20120045436
    Abstract: Disclosed are CD70 binding agents, such as humanized anti-CD70 antibodies and fragments and derivatives, that exert a cytotoxic, cytostatic or immunomodulatory on CD70 expressing cells, as well as pharmaceutical compositions and kits comprising the antibody, fragment or derivative. Also disclosed are methods for the treatment of CD70-expressing cancers and immunological disorders, comprising administering to a subject the CD70 binding agents or pharmaceutical compositions.
    Type: Application
    Filed: October 11, 2011
    Publication date: February 23, 2012
    Applicant: Seattle Genetics, Inc.
    Inventors: Charlotte McDonagh, Paul Carter, Julie McEarchern, Che-Leung Law
  • Humanized anti-CD70 binding agents and uses thereof
    Patent number: 8067546
    Abstract: Disclosed are CD70 binding agents, such as humanized anti-CD70 antibodies and fragments and derivatives, that exert a cytotoxic, cytostatic or immunomodulatory on CD70 expressing cells, as well as pharmaceutical compositions and kits comprising the antibody, fragment or derivative. Also disclosed are methods for the treatment of CD70-expressing cancers and immunological disorders, comprising administering to a subject the CD70 binding agents or pharmaceutical compositions.
    Type: Grant
    Filed: April 19, 2006
    Date of Patent: November 29, 2011
    Assignee: Seattle Genetics, Inc.
    Inventors: Charlotte McDonagh, Paul Carter, Julie McEarchern, Che-Leung Law
  • ANTI-CD70 ANTIBODY-DRUG CONJUGATES AND THEIR USE FOR THE TREATMENT AND PREVENTION OF CANCER AND IMMUNE DISORDERS
    Publication number: 20110150908
    Abstract: Disclosed are anti-CD70 antibodies and derivatives thereof conjugated to cytotoxic, immunosuppressive, or other therapeutic agents, as well as pharmaceutical compositions and kits comprising the antibody- and antibody derivative-drug conjugates. Also disclosed are methods, for the treatment of CD70-expressing cancers and immunological disorders, comprising administering to a subject the disclosed pharmaceutical compositions.
    Type: Application
    Filed: September 27, 2010
    Publication date: June 23, 2011
    Applicant: SEATTLE GENETICS, INC.
    Inventors: CHE-LEUNG LAW, JULIE MCEARCHERN, JONATHAN G. DRACHMAN
  • TREATMENT OF PSORIATIC ARTHRITIS WITH ANTI-CD70 ANTIBODY
    Publication number: 20100129362
    Abstract: Disclosed are CD70 binding agents, such as anti-CD70 antibodies and derivatives, that induce a cytotoxic, cytostatic or immunomodulatory without conjugation to a therapeutic agents as well as pharmaceutical compositions and kits comprising the antibody or derivative. Also disclosed are methods for the treatment of psoriatic arthritis comprising administering the CD70 binding agents to a subject.
    Type: Application
    Filed: November 16, 2009
    Publication date: May 27, 2010
    Applicant: SEATTLE GENETICS, INC.
    Inventors: CHE-LEUNG LAW, JULIE MCEARCHERN, ALAN F. WAHL
  • Anti-CD70 antibody and its use for the treatment and prevention of cancer and immune disorders
    Patent number: 7641903
    Abstract: Disclosed are CD70 binding agents, such as anti-CD70 antibodies and derivatives, that induce a cytotoxic, cytostatic or immunomodulatory without conjugation to a therapeutic agents as well as pharmaceutical compositions and kits comprising the antibody or derivative. Also disclosed are methods for the treatment and prevention of CD70-expressing cancers and immunological disorders comprising administering the CD70 binding agents to a subject.
    Type: Grant
    Filed: April 13, 2007
    Date of Patent: January 5, 2010
    Assignee: Seattle Genetics, Inc.
    Inventors: Che-Leung Law, Julie McEarchern, Alan F. Wahl
  • Anti-CD70 Antibody And Its Use For The Treatment And Prevention Of Cancer And Immune Disorders
    Publication number: 20090232806
    Abstract: Disclosed are CD70 binding agents, such as anti-CD70 antibodies and derivatives, that induce a cytotoxic, cytostatic or immunomodulatory without conjugation to a therapeutic agents as well as pharmaceutical compositions and kits comprising the antibody or derivative. Also disclosed are methods for the treatment and prevention of CD70-expressing cancers and immunological disorders comprising administering the CD70 binding agents to a subject.
    Type: Application
    Filed: February 12, 2009
    Publication date: September 17, 2009
    Applicant: Seattle Genetics, Inc.
    Inventors: Che-Leung Law, Julie McEarchern, Alan F. Wahl
  • Anti-CD70 Antibody and Its Use for the Treatment of Cancer and Immune Disorders
    Publication number: 20090074772
    Abstract: Disclosed are CD70 binding agents, such as anti-CD70 antibodies and derivatives, that induce a cytotoxic, cytostatic or immunosuppressive without conjugation to a therapeutic agents, as well as pharmaceutical compositions and kits comprising the antibody or derivative. Also disclosed are methods for the treatment and prevention of CD70-expressing cancers and immunological disorders comprising administering to a subject the CD70-binding agent.
    Type: Application
    Filed: November 5, 2008
    Publication date: March 19, 2009
    Applicant: Seattle Genetics, Inc.
    Inventors: Che-Leung Law, Julie McEarchern, Alan F. Wahl